Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis | Zendy

Laurent Azoulay | Zendy; Kristian B. Filion | Zendy; Robert W. Platt | Zendy; Matthew Dahl | Zendy; Colin R. Dormuth | Zendy; Kristin K. Clemens | Zendy; Madéleine Durand | Zendy; Nianping Hu | Zendy; David N. Juurlink | Zendy; J. Michael Paterson | Zendy; Laura E. Targownik | Zendy; Tanvir Chowdhury Turin | Zendy; Pierre Ernst | Zendy; Samy Suissa | Zendy; Brenda R. Hemmelgarn | Zendy; Gary Teare | Zendy; Patrícia Caetano | Zendy; Dan Château | Zendy; David Henry | Zendy; Jacques LeLorier | Zendy; Adrian R. Levy | Zendy; Ingrid Sketris | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis

Author(s) -

Laurent Azoulay,

Kristian B. Filion,

Robert W. Platt,

Matthew Dahl,

Colin R. Dormuth,

Kristin K. Clemens,

Madéleine Durand,

Nianping Hu,

David N. Juurlink,

J. Michael Paterson,

Laura E. Targownik,

Tanvir Chowdhury Turin,

Pierre Ernst,

Samy Suissa,

Brenda R. Hemmelgarn,

Gary Teare,

Patrícia Caetano,

Dan Château,

David Henry,

Jacques LeLorier,

Adrian R. Levy,

Ingrid Sketris

Publication year - 2016

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2016.1522

Subject(s) - medicine , incretin , acute pancreatitis , type 2 diabetes , hazard ratio , cohort , diabetes mellitus , cohort study , pancreatitis , population , pharmacoepidemiology , pharmacology , confidence interval , endocrinology , medical prescription , environmental health

The association between incretin-based drugs, such as dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists, and acute pancreatitis is controversial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research